Loading…
VENTOLIN ACCUHALER is a brand name for Albuterol (also known as Salbutamol). The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Ventolin Accuhaler is indicated in adults, adolescents and children aged 4 to 11 years. Ventolin Accuhaler can be used in the management of asthma, bronchospasm and/or reversible airways obstruction. Ventolin Accuhaler is particularly suitable for the relief of asthma symptoms. It should be used to relieve symptoms…
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults (including the elderly) For the relief of acute bronchospasm, 200 micrograms as a single dose. The maximum daily dose is 200 micrograms four times a day. To prevent allergen- or exercise-induced symptoms, 200 micrograms should be taken 10-15 minutes before challenge.
Paediatric Population Relief of acute bronchospasm Children aged 4 to 11 years 200 micrograms as required.
Children aged 12 years and over:
Dose as per adult population. Prevention of allergen or exercise-induced bronchospasm Children aged 4 to 11 years 200 micrograms before challenge or exertion.
Children aged 12 years and over:
Dose as per adult population. Chronic therapy Children aged 4 to 11 years 200 micrograms four times a day. On-demand use of Ventolin Accuhaler should not exceed four times daily. 4).
Children aged 12 years and over:
Dose as per adult population. Method of Administration Ventolin Accuhaler is for inhalation use only. Ventolin Accuhaler is suitable for many patients including those who cannot use a metered-dose inhaler successfully. Salbutamol inhaled formulations are administered by the inhaled route only, to be breathed in through the mouth.
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000) and very rare (<1/10,000) including isolated reports.
Very common and common events were generally determined from clinical trial data. Rare, very rare and unknown events were generally determined from spontaneous data.
Immune system disorders Very rare:
Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse Metabolism and nutrition disorders Rare: Hypokalaemia. Potentially serious hypokalaemia may result from beta2 agonist therapy.
Nervous system disorders Common:
Tremor, headache.
Very rare:
Hyperactivity.
Cardiac disorders Common:
Tachycardia.
Uncommon:
Palpitations. 4) Vascular disorders Rare: Peripheral vasodilatation.
Respiratory, thoracic and mediastinal disorders Very rare:
Paradoxical bronchospasm.
Gastrointestinal disorders Uncommon:
Mouth and throat irritation.
Musculoskeletal and connective tissue disorders Uncommon:
Muscle cramps. * reported spontaneously in post-marketing data therefore frequency regarded as unknown Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma. Severe asthma requires regular medical assessment, including lung- function testing, as patients are at risk of severe attacks and even death.
Physicians should consider using the maximum recommended dose of inhaled corticosteroid and/or oral corticosteroid therapy in these patients. , inhaled corticosteroids) should be advised to continue taking their anti-inflammatory medication even when symptoms decrease, and they do not require Ventolin Accuhaler.
Increasing use of bronchodilators, in particular short-acting inhaled β2-agonists to relieve symptoms, indicates deterioration of asthma control, and patients should be warned to seek medical advice as soon as possible. Under these conditions, the patient's therapy plan should be reassessed.
Overuse of short-acting beta-agonists may mask the progression of the underlying disease and contribute to deteriorating asthma control, leading to an increased risk of severe asthma exacerbations and mortality. , daytime symptoms, night-time awakening, and activity limitation due to asthma) for proper treatment adjustment as these patients are at risk for overuse of salbutamol.
Sudden and progressive deterioration in asthma control is potentially life-threatening and consideration should be given to starting or increasing corticosteroid therapy. In patients considered at risk, daily peak flow monitoring may be instituted.
The patient should be instructed to seek medical advice if short-acting relief bronchodilator treatment becomes less effective, or more inhalations than usual are required. In the event of a previously effective dose of inhaled salbutamol now failing to give relief for a duration of at least three hours following administration, the patient should be advised to promptly seek medical advice in order that any necessary additional steps may be taken.
1. Non-IV formulations of salbutamol must not be used to arrest uncomplicated premature labour or threatened abortion. Ventolin Accuhaler is contraindicated in patients with severe milk-protein allergy.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Albuterol in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
g. higher doses of inhaled corticosteroid or a course of oral corticosteroid). Severe exacerbations of asthma must be treated in the normal way. Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol.
g. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin.
Salbutamol should be administered cautiously to patients suffering from thyrotoxicosis. Increasing use of β2-agonists may be a sign of worsening asthma. Under these conditions a reassessment of the patient’s therapy plan may be required and concomitant corticosteroid therapy should be considered.
As there may be adverse effects associated with excessive dosing, the dosage or frequency of administration should only be increased on medical advice. Potentially serious hypokalaemia may result from β2-agonist therapy, mainly from parenteral and nebulised administration.
Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations.
As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with an alternative presentation or a different fast-acting inhaled bronchodilator.
Ventolin Accuhaler should be discontinued immediately, the patient assessed, and if necessary a different fast-acting bronchodilator instituted for on-going use. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.